# SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07683221/  
OnCo record `nct07683221` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sintilimab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Shandong Cancer Hospital and Institute, not yet recruiting.

## Summary

SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT07683221 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 47 participants, started 2026-07-15 and due to reach its primary completion in 2029-07-15. Interventions recorded: SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival (PFS). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07683221
- Phase: 2
- Setting: Stereotactic Body Radiotherapy Followed by Ipilimumab N01 Plus Sintilimab in Combination With Nab-Paclitaxel and Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer: A Phase II, Prospective, Single-Arm Exploratory Clinical Trial
- Sponsor: Shandong Cancer Hospital and Institute
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT07683221: https://clinicaltrials.gov/study/NCT07683221

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07683221.json